Motif Bio

Motif Bio PLC is a United Kingdom-based clinical-stage biopharmaceutical company which specializes in developing antibiotics designed to be effective against serious and life-threatening infections caused by multi-drug resistant bacteria. The Company has a lead antibiotic candidate, Iclaprim, and MTF-001, a preclinical program.-based on iclaprim and other lead compounds, the Company is engaged in the development of a lead series with the objective of identifying a DHFRi that is effective against a broad spectrum of gram positive bacteria, including those resistant to available antibiotics, that can be administered once daily in injectable (I/V) and oral (pill) formulations. The Company's other programs include programs in various-stages of development by building a portfolio of antibiotics by licensing drug candidates from organizations specialized in antibacterial research.
London, GB
1 (est)
Motif Bio is headquartered in London, GB

Motif Bio Locations

London, GB
New York, US

Motif Bio Metrics

Motif Bio Summary

Market capitalization

£26.1 M

Closing share price

Motif Bio's current market capitalization is £26.1 M.

Motif Bio Market Value History

Motif Bio News

Motif Bio Company Life

You may also be interested in